ATE69378T1 - Pharmazeutische zusammensetzungen. - Google Patents

Pharmazeutische zusammensetzungen.

Info

Publication number
ATE69378T1
ATE69378T1 AT87300630T AT87300630T ATE69378T1 AT E69378 T1 ATE69378 T1 AT E69378T1 AT 87300630 T AT87300630 T AT 87300630T AT 87300630 T AT87300630 T AT 87300630T AT E69378 T1 ATE69378 T1 AT E69378T1
Authority
AT
Austria
Prior art keywords
treatment
conditions
physiologically acceptable
pharmaceutical compositions
essential fatty
Prior art date
Application number
AT87300630T
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Pharma Ltd filed Critical Scotia Pharma Ltd
Application granted granted Critical
Publication of ATE69378T1 publication Critical patent/ATE69378T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87300630T 1986-01-27 1987-01-26 Pharmazeutische zusammensetzungen. ATE69378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868601915A GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions
EP87300630A EP0234733B1 (de) 1986-01-27 1987-01-26 Pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE69378T1 true ATE69378T1 (de) 1991-11-15

Family

ID=10591997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87300630T ATE69378T1 (de) 1986-01-27 1987-01-26 Pharmazeutische zusammensetzungen.

Country Status (13)

Country Link
US (2) US4753964A (de)
EP (1) EP0234733B1 (de)
JP (1) JPS62185018A (de)
AT (1) ATE69378T1 (de)
AU (1) AU593317B2 (de)
DE (1) DE3774449D1 (de)
ES (1) ES2040242T3 (de)
GB (1) GB8601915D0 (de)
GR (1) GR3003120T3 (de)
HK (1) HK127893A (de)
IE (1) IE59606B1 (de)
SG (1) SG114293G (de)
ZA (1) ZA87560B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599840A (en) * 1986-11-26 1997-02-04 Bar Ilan University Physiologically active and nutritional composition
US5120763A (en) * 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
DE3863678D1 (de) * 1987-04-27 1991-08-22 Efamol Holdings Lithiumsalze enthaltende pharmazeutische zubereitungen.
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US4851398A (en) * 1987-09-30 1989-07-25 Elena Avram Bismuth containing pharmaceutical compositions
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
IL91802A (en) * 1988-10-27 1994-05-30 Univ Bar Ilan Preparations containing linoleic acid history for the treatment of Alzheimer's, similar brain diseases, and epilepsy
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
SG49307A1 (en) * 1991-01-24 1998-05-18 Martek Corp Microbial oil mixtures and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
AU698101B2 (en) * 1993-06-01 1998-10-22 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
EP0730463B1 (de) * 1993-11-26 2000-02-02 Karla Lehmann Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
EP0726073A3 (de) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
JPH11279066A (ja) * 1998-03-25 1999-10-12 Mitsubishi Chemical Corp リチウム塩を有効成分とする神経細胞死抑制剤
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CA2645647C (en) * 2005-05-23 2016-07-12 Massachusetts Institute Of Technology Compositions containing pufa and/or uridine and methods of use thereof
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
CN103211807A (zh) * 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
WO2007086931A1 (en) * 2006-01-24 2007-08-02 Majid Fotuhi Dosage regimen and medicament for preventing of reducing risk of onset or progression of dementia by administration of specific vitamins and nsaid
CN101478977B (zh) * 2006-03-29 2013-03-27 维拉科治疗学控股有限公司 神经变性疾病的治疗
JPWO2008081989A1 (ja) 2006-12-28 2010-04-30 サントリーホールディングス株式会社 神経再生剤
US20080181937A1 (en) * 2007-01-29 2008-07-31 Majid Fotuhi Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
KR101397554B1 (ko) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
BRPI1000970A2 (pt) * 2010-04-07 2011-11-29 Fundacao Arnaldo Vieira De Carvalho composição farmacêutica para o tratamento da doença de alzheimer, processo para sua obtenção e uso
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
SG11201507188QA (en) * 2014-03-24 2015-10-29 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment
JP2016023163A (ja) * 2014-07-22 2016-02-08 出光興産株式会社 γ−リノレン酸を含む神経細胞の酸化ストレス軽減剤
RU2587617C1 (ru) * 2014-12-23 2016-06-20 Ольга Алексеевна Громова Способ профилактики и лечения нейродегенеративной патологии и сосудистой деменции
WO2016191323A1 (en) 2015-05-22 2016-12-01 University Of South Florida Lithium co-crystals for treatment of neuropsychiatric disorders
CN109562089A (zh) * 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸锂用于治疗中枢神经系统疾病的用途
JPWO2018221244A1 (ja) * 2017-05-30 2019-11-21 森永乳業株式会社 脳機能改善用組成物
WO2020237203A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels

Also Published As

Publication number Publication date
HK127893A (en) 1993-11-26
ZA87560B (en) 1987-09-30
EP0234733A1 (de) 1987-09-02
IE870194L (en) 1987-07-27
US4753964A (en) 1988-06-28
JPS62185018A (ja) 1987-08-13
GB8601915D0 (en) 1986-03-05
AU593317B2 (en) 1990-02-08
GR3003120T3 (en) 1993-02-17
EP0234733B1 (de) 1991-11-13
SG114293G (en) 1994-01-21
AU6767587A (en) 1987-07-30
IE59606B1 (en) 1994-03-09
DE3774449D1 (de) 1991-12-19
US4810497A (en) 1989-03-07
ES2040242T3 (es) 1993-10-16

Similar Documents

Publication Publication Date Title
DE3774449D1 (de) Pharmazeutische zusammensetzungen.
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ATE135909T1 (de) Verfahren zur behandlung von akne
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
KR950000141A (ko) 피부병 치료용 약제조성물 제조를 위한 방향족산을 함유한 l- 카르니틴 o-에스테르의 용도
EP0009548A3 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them, and their starting derivatives and their preparation
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
ATE160090T1 (de) Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
GR3006606T3 (de)
EP0383481A3 (de) Bukkale Anästhetika
IT1210874B (it) Sale di magnesio dell'acido chenodesossicolico e dell'acido ursodesossicolico, processo per lasua preparazione e composizioni terapeutiche che lo contengono come principio attivo.
US4156003A (en) Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
GB1463260A (en) Pharmacologically active acetic acid derivative
RU93058599A (ru) Новые диметиламинооксиалкандифосфоновые кислоты и их соли, способ их получения, содержащие их фармацевтические составы, применение

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time